Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBT: 2019-2024

Historic EBT for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$334.7 million.

  • Lyell Immunopharma's EBT rose 23.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of -$334.7 million for FY2024, which is 49.71% down from last year.
  • Latest data reveals that Lyell Immunopharma reported EBT of -$334.7 million as of FY2024, which was down 49.71% from -$223.6 million recorded in FY2023.
  • Over the past 5 years, Lyell Immunopharma's EBT peaked at -$180.0 million during FY2022, and registered a low of -$334.7 million during FY2024.
  • In the last 3 years, Lyell Immunopharma's EBT had a median value of -$223.6 million in 2023 and averaged -$246.1 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 119.22% in 2020, then increased by 15.73% in 2022.
  • Over the past 5 years, Lyell Immunopharma's EBT (Yearly) stood at -$206.0 million in 2020, then fell by 3.70% to -$213.6 million in 2021, then grew by 15.73% to -$180.0 million in 2022, then fell by 24.19% to -$223.6 million in 2023, then slumped by 49.71% to -$334.7 million in 2024.